OUR MISSION
· Remove the fear and pain associated with opioid withdrawal.
· Provide a compassionate and effective detox option.
· Increase treatment participation.
About Us
On May 2nd 2018, the Morph Device was granted a 510(k) clearance by the U.S. Food & Drug Administration. The device was cleared for Therapeutic Neuromodulation Systems to use as an aid in the treatment of opioid withdrawal.
Therapeutic Neuromodulation Systems, LLC is a U.S.-based sales and marketing organization. We are committed to our mission of using the Morph Device to increase treatment participation and remove the fear and pain associated with opioid withdrawal. Our experienced team of leaders are focused on creating a paradigm shift from traditional detox to the more humane method of the Morph Device.
We are passionate about establishing a vast distribution network of providers to make the Morph Device easily accessible to detox patients.
Leadership Team
The Therapeutic Neuromodulation Systems leadership team is comprised of successful professionals and entrepreneurs in the medical device field.
Arnold Rougee, President & Founder
Arnold Rougee has 27+ years of experience the private equity/mergers & acquisitions field. Mr. Rougee has initiated acquisitions in a variety of business sectors including the recycling industry, 3D graphic technology, film and production, construction services, industrial services, minerals and mining and a national car wash business. He has also played a major role in taking many of these ventures public. Mr. Rougee specializes in incubating emerging technologies, raising investment capital and bringing these technologies to market. He is experienced with new business development, contract negotiations, contract management and construction project management.
William J. Fisher, Esq., General Counsel
William Fisher serves as the President and CEO of DSRA, CX Solutions, Bass Reports and Central Surveys. Mr. Fisher is keenly engaged in the strategic consulting, new business development and client relations for these companies. Under Mr. Fisher’s leadership, DSRA has established long-term research and consulting relationships with a host of Fortune 500 firms. Mr. Fisher is an experienced corporate attorney in the mergers & acquisitions field, with transactions totally nearly $200 million dollars. Mr. Fisher received his Juris Doctorate from Texas A&M University School of Law and is licensed to practice in several jurisdictions. He is a member of the American Bar Association, The American Trial Lawyers Association and one of a handful of attorneys licensed to practice before the United States Supreme Court. Mr. Fisher has also authored multiple business articles in scholarly publications like Texas Lawyer.
Matt Lawhon, JD, FDA Compliance Attorney
Matt Lawhon serves as external legal counsel. Mr. Lawhon’s unique background in both law enforcement and legal counsel delivers the necessary experience to help Therapeutic Neuromodulation Systems, LLC (TNS) navigate the heavily regulated environment. For over a decade, Mr. Lawhon investigated healthcare fraud and abuse – first as a senior investigator for the Medicare Benefits Integrity Contractor in Texas (now UPIC) and then as a criminal investigator for the Texas Attorney General’s Medicaid Fraud Control Unit (MFCU). As an accomplished healthcare investigator, Mr. Lawhon developed an in-depth knowledge of the major healthcare laws governing healthcare delivery practices such as Anti-Kickback, Stark, the False Claims Act and the Sunshine Act. As an attorney, Mr. Lawhon uses this valuable knowledge to provide the guidance and counsel necessary to allow TNS to grow as a leader in the addiction treatment industry while maintaining compliance under the law. Mr. Lawhon is the owner of the M B Lawhon Law Firm PLLC. Bar Admissions: State of Texas, Northern District of Texas.